Comparable stake leader
VANGUARD CAPITAL MANAGEMENT LLC
SEC ownership of JOHNSON & JOHNSON
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000200406.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- JNJ on NYSE
- Parsed ownership sources
- 13D/G and 13F
- Largest SEC-reported holder
- VANGUARD CAPITAL MANAGEMENT LLC
- Latest 13D/G holder
- VANGUARD CAPITAL MANAGEMENT LLC
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0000200406
- Issuer location
- New Brunswick, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of JOHNSON & JOHNSON (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD CAPITAL MANAGEME...
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
Lead comparable stake: 7.5%
13D/G row: VANGUARD CAPITAL MANAGEMENT LLC
Showing 1-8 of 50 holder rows.
Quick read
VANGUARD CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 7.5%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
VANGUARD CAPITAL MANAGEMENT LLC
7.5%
BlackRock, Inc.
8.8%
STATE STREET CORP
5.5%
VANGUARD PORTFOLIO MANAGEMENT LLC
2.6%
JPMORGAN CHASE & CO
2.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
7.5%
|
$42,983,007,015
180,631,228 shares
|
$0 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
8.8%
|
$52,159,962,657
213,385,546 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
Company
|
5.5%
|
$32,626,943,839
133,476,288 shares
|
— | 31 Mar 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
2.6%
|
$15,525,468,737
63,514,436 shares
|
— | 31 Mar 2026 |
| JPMORGAN CHASE & CO |
13F
Company
|
2.6%
|
$15,300,233,008
63,096,344 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
2.5%
|
$14,422,987,278
59,164,862 shares
|
— | 31 Mar 2026 |
| MORGAN STANLEY |
13F
Company
|
1.9%
|
$10,931,642,638
44,721,167 shares
|
— | 31 Mar 2026 |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO |
13F
Company
|
1.3%
|
$7,722,092,307
31,590,952 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$123,099,382.
Buys
$257,688
Insiders: 1
Sells
$123,357,070
Insiders: 8
Net
-$123,099,382
Shares: -578,605
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,250
Shares: 579,855
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 339,882 | $0 | $80,476,339 | -$80,476,339 |
| 6-9 | 1,250 | 21,721 | $257,688 | $4,185,793 | -$3,928,106 |
| 9-12 | 0 | 218,252 | $0 | $38,694,938 | -$38,694,938 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 36 reporting-owner rows connected to JOHNSON & JOHNSON. Open a relationship link for the CIK-to-CIK filing trail.
Rows
36
Largest Forms 3/4/5 holder
Alex Gorsky
Net 12M change
-$123,099,382
Latest report
01 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Alex Gorsky | Director | $132,153,735 | Mixed | 17 Jan 2023 | ||
| Joaquin Duato | CEO and Chairman of the Board, Director | $88,349,558 | -$44,671,548 | -34% | Mixed | 13 Feb 2026 |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | $48,204,011 | -$10,040,883 | -17% | Mixed | 13 Feb 2026 |
| Michael H. Ullmann | Exec VP, General Counsel | $31,906,242 | Mixed | 14 Feb 2022 | ||
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | $28,204,107 | Mixed | 13 Feb 2026 | ||
| Peter Fasolo | Exec VP, Chief HR Officer | $21,756,253 | Mixed | 15 Feb 2024 | ||
| Joseph J. Wolk | Exec VP, CFO | $20,446,898 | -$24,743,398 | -55% | Mixed | 13 Feb 2026 |
| Thibaut Mongon | Exec VP, WW Chair, Cons Health | $15,974,106 | Mixed | 13 Feb 2023 | ||
| John C. Reed | EVP, Innovative Medicine, R&D | $13,814,519 | -$20,420,856 | -60% | Mixed | 01 May 2026 |
| Mathai Mammen | EVP, Pharm, R&D | $10,751,687 | Mixed | 14 Feb 2022 | ||
| James D. Swanson | Evp, Cio | $10,018,736 | -$15,109,759 | -60% | Mixed | 13 Feb 2026 |
| William Hait | EVP, Chief EI and Med Officer | $9,578,502 | Mixed | 15 Feb 2024 | ||
| Ashley McEvoy | EVP, WW Chair, MedTech | $9,484,760 | Mixed | 23 Aug 2023 | ||
| Vanessa Broadhurst | EVP, Global Corp Affairs | $8,400,124 | -$1,508,288 | -15% | Mixed | 13 Feb 2026 |
| Timothy Schmid | EVP, WW Chair, MedTech | $6,911,910 | -$5,852,268 | -46% | Mixed | 20 Feb 2026 |
| Elizabeth Forminard | EVP, Chief Legal Officer | $6,235,591 | Mixed | 13 Feb 2026 | ||
| Robert J. Decker | VP Corporate Controller | $6,221,796 | -$1,010,070 | -14% | Mixed | 27 Feb 2026 |
| Kristen Mulholland | EVP, Chief HR Officer | $5,096,972 | Mixed | 13 Feb 2026 | ||
| A. Eugene Washington | Director | $4,542,828 | Mixed | 07 Mar 2023 | ||
| Ronald A. Williams | Director | $4,082,264 | Mixed | 15 Feb 2022 |
Recent insider transactions for JOHNSON & JOHNSON
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| John C. Reed | JNJ | Common Stock | Tax liability | -30.6% | -11,002 | 24,911 | 01 May 2026 | Direct | ||
| John C. Reed | JNJ | Common Stock | Options Exercise | 237% | 25,255 | 35,913 | 01 May 2026 | Direct | ||
| John C. Reed | JNJ | Restricted Share Units | Options Exercise | -100% | -25,255 | 0 | 01 May 2026 | Direct | ||
| Eugene A. Woods | JNJ | Deferred Share Units | Award | 18.6% | 975 | 6,215 | 23 Apr 2026 | Direct | ||
| Nadja Y. West | JNJ | Deferred Share Units | Award | 14.4% | 975 | 7,730 | 23 Apr 2026 | Direct | ||
| Mark A. Weinberger | JNJ | Deferred Share Units | Award | 8.84% | 975 | 12,010 | 23 Apr 2026 | Direct | ||
| Daniel E. Pinto | JNJ | Deferred Share Units | Award | 370.5% | 1,712 | 2,174 | 23 Apr 2026 | Direct | ||
| John G. Morikis | JNJ | Deferred Share Units | Award | 1,540 | 1,540 | 23 Apr 2026 | Direct | |||
| Mark B. McClellan | JNJ | Deferred Share Units | Award | 4.8% | 975 | 21,279 | 23 Apr 2026 | Direct | ||
| Hubert Joly | JNJ | Deferred Share Units | Award | 11.9% | 975 | 9,184 | 23 Apr 2026 | Direct | ||
| Paula A. Johnson | JNJ | Deferred Share Units | Award | 22.2% | 975 | 5,359 | 23 Apr 2026 | Direct | ||
| Marillyn A. Hewson | JNJ | Deferred Share Units | Award | 6.72% | 975 | 15,488 | 23 Apr 2026 | Direct | ||
| Jennifer A. Doudna | JNJ | Deferred Share Units | Award | 9.82% | 975 | 10,899 | 23 Apr 2026 | Direct | ||
| Mary C. Beckerle | JNJ | Deferred Share Units | Award | 6.16% | 975 | 16,798 | 23 Apr 2026 | Direct | ||
| Marillyn A. Hewson | JNJ | Deferred Share Units | Award | 1.44% | 206 | 14,513 | 10 Mar 2026 | Direct | ||
| Daniel E. Pinto | JNJ | Deferred Share Units | Award | 38.8% | 129 | 462 | 10 Mar 2026 | Direct | ||
| Eugene A. Woods | JNJ | Deferred Share Units | Award | 3.05% | 155 | 5,240 | 10 Mar 2026 | Direct | ||
| Robert J. Decker | JNJ | Common Stock | Sale | -14.7% | $1,010,070 | $247.87 | -4,075 | 23,682 | 27 Feb 2026 | Direct |
| Robert J. Decker | JNJ | Common Stock | Options Exercise | 17.2% | 4,075 | 27,757 | 27 Feb 2026 | Direct | ||
| Robert J. Decker | JNJ | Employee Stock Options (Right to Buy) | Options Exercise | -100% | -4,075 | 0 | 27 Feb 2026 | Direct | ||
| Timothy Schmid | JNJ | Common Stock | Sale | -4.94% | $324,763 | $245.66 | -1,322 | 25,447 | 20 Feb 2026 | Direct |
| Timothy Schmid | JNJ | Common Stock | Sale | -45.8% | $5,527,506 | $244.33 | -22,623 | 26,769 | 18 Feb 2026 | Direct |
| Timothy Schmid | JNJ | Common Stock | Options Exercise | 127.3% | 22,623 | 40,394 | 18 Feb 2026 | Direct | ||
| Timothy Schmid | JNJ | Employee Stock Options (Right to Buy) | Options Exercise | -100% | -22,623 | 0 | 18 Feb 2026 | Direct | ||
| James D. Swanson | JNJ | Common Stock | Sale | -44.4% | $4,980,447 | $242.70 | -20,521 | 25,698 | 17 Feb 2026 | Direct |
| James D. Swanson | JNJ | Common Stock | Options Exercise | 79.8% | 20,521 | 46,219 | 17 Feb 2026 | Direct | ||
| James D. Swanson | JNJ | Employee Stock Options (Right to Buy) | Options Exercise | -100% | -20,521 | 0 | 17 Feb 2026 | Direct | ||
| Joseph J. Wolk | JNJ | Common Stock | Sale | -86.5% | $21,767,827 | $242.80 | -89,654 | 14,000 | 17 Feb 2026 | Direct |
| Joseph J. Wolk | JNJ | Common Stock | Options Exercise | 845.2% | 64,693 | 72,347 | 17 Feb 2026 | Direct | ||
| Joseph J. Wolk | JNJ | Employee Stock Options (Right to Buy) | Options Exercise | -100% | -64,693 | 0 | 17 Feb 2026 | Direct | ||
| John C. Reed | JNJ | Common Stock | Sale | -83.5% | $13,105,233 | $243.00 | -53,931 | 10,658 | 17 Feb 2026 | Direct |
| John C. Reed | JNJ | Common Stock | Options Exercise | 51,648 | 42,868 | 17 Feb 2026 | Direct | |||
| John C. Reed | JNJ | Employee Stock Options (Right to Buy) | Options Exercise | -70.4% | -51,648 | 21,721 | 17 Feb 2026 | Direct | ||
| Vanessa Broadhurst | JNJ | Common Stock | Sale | -21.2% | $1,508,288 | $243.39 | -6,197 | 23,003 | 17 Feb 2026 | Direct |
| James D. Swanson | JNJ | Common Stock | Tax liability | -2.03% | -523 | 25,298 | 15 Feb 2026 | Direct | ||
| James D. Swanson | JNJ | Common Stock | Options Exercise | 4.84% | 1,201 | 26,007 | 15 Feb 2026 | Direct | ||
| James D. Swanson | JNJ | Restricted Share Units | Award | 1,397 | 1,397 | 15 Feb 2026 | Direct | |||
| James D. Swanson | JNJ | Employee Stock Options (Right to Buy) | Award | 19,449 | 19,449 | 15 Feb 2026 | Direct | |||
| James D. Swanson | JNJ | Restricted Share Units | Options Exercise | -71% | -1,201 | 491 | 15 Feb 2026 | Direct | ||
| Kathryn E. Wengel | JNJ | Common Stock | Tax liability | -0.55% | -635 | 113,978 | 15 Feb 2026 | Direct | ||
| Kathryn E. Wengel | JNJ | Common Stock | Options Exercise | 1.09% | 1,241 | 114,613 | 15 Feb 2026 | Direct | ||
| Kathryn E. Wengel | JNJ | Restricted Share Units | Award | 1,217 | 1,217 | 15 Feb 2026 | Direct | |||
| Kathryn E. Wengel | JNJ | Employee Stock Options (Right to Buy) | Award | 16,945 | 16,945 | 15 Feb 2026 | Direct | |||
| Kathryn E. Wengel | JNJ | Restricted Share Units | Options Exercise | -67.2% | -1,241 | 606 | 15 Feb 2026 | Direct | ||
| Kristen Mulholland | JNJ | Common Stock | Tax liability | -2.12% | -423 | 19,506 | 15 Feb 2026 | Direct | ||
| Kristen Mulholland | JNJ | Common Stock | Options Exercise | 5.21% | 994 | 20,081 | 15 Feb 2026 | Direct | ||
| Kristen Mulholland | JNJ | Restricted Share Units | Award | 1,459 | 1,459 | 15 Feb 2026 | Direct | |||
| Kristen Mulholland | JNJ | Employee Stock Options (Right to Buy) | Award | 20,322 | 20,322 | 15 Feb 2026 | Direct | |||
| Kristen Mulholland | JNJ | Restricted Share Units | Options Exercise | -70.4% | -994 | 418 | 15 Feb 2026 | Direct | ||
| Joseph J. Wolk | JNJ | Common Stock | Tax liability | -4.23% | -1,675 | 37,900 | 15 Feb 2026 | Direct |
* marks a reported price that did not pass the local price check.